Loading…
Summit Research Peptides was cited for selling unapproved new drugs (Semaglutide, Retatrutide, Cagrilintide, Tirzepatide, and Mazdutide) in violation of the Federal Food, Drug, and Cosmetic Act. Despite labeling the products as "research use only" and "research chemicals," the company's website and social media marketing made therapeutic claims establishing these products were intended for human use to treat type 2 diabetes, obesity, and related conditions. The FDA determined these peptides met the definition of drugs because they were intended to prevent, treat, cure disease conditions, or affect the structure or function of the body, yet lacked required FDA approval before being introduced into interstate commerce.